Hepatic Encephalopathy Treatment with L-Ornithine L-Aspartate (LOLA)

Intravenous LOLA Administration

The recommended dosage of intravenous LOLA for the treatment of hepatic encephalopathy is 30 g/day, which has been shown to effectively lower plasma ammonia concentrations and improve symptoms 1
Intravenous LOLA (30 g/day) in combination with lactulose leads to a lower grade of hepatic encephalopathy within 1-4 days of treatment and shorter duration until symptom recovery compared to lactulose alone 2
For patients with West-Haven criteria grade 1-2 hepatic encephalopathy, intravenous LOLA lowers number connection test (NCT)-A time and plasma ammonia concentrations more effectively than placebo 3

Oral LOLA can lower the NCT-A time and plasma ammonia concentrations, though further studies are required to fully assess its efficacy in managing overt hepatic encephalopathy 1

LOLA works by providing substrates (ornithine and aspartate) that are important for metabolizing ammonia to urea and glutamine 2
This mechanism helps lower plasma ammonia concentrations, which produces improvements in hepatic encephalopathy symptoms 3

LOLA should be considered as part of a comprehensive treatment approach that may include lactulose (20-30 g orally 3-4 times per day) 4, 5

For overt hepatic encephalopathy requiring intravenous therapy: Administer LOLA 30 g/day intravenously 1, 2
Monitor clinical response through measurement of plasma ammonia levels 3 and number connection test performance 3
Consider combination therapy with lactulose for enhanced efficacy 2